Jens Kuhle1, Bardia Nourbakhsh2, Donna Grant2, Steve Morant2, Christian Barro2, Özgür Yaldizli2, Daniel Pelletier2, Gavin Giovannoni2, Emmanuelle Waubant2, Sharmilee Gnanapavan2. 1. From Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK. jens.kuhle@usb.ch. 2. From Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
Abstract
OBJECTIVE: To investigate a potential effect of riluzole on serum neurofilaments (Nf) compared to placebo and the relationship between longitudinal clinical and MRI outcomes and serum Nf levels. METHODS: Serum samples were obtained from participants enrolled in a randomized double-blind trial of neuroprotection with riluzole vs placebo as an add-on to weekly interferon-β (IFN-β)-1a IM initiated 3 months after randomization. Nf measurements were performed by ELISA and electrochemiluminescence immunoassay. RESULTS: Longitudinal serum samples were available from 22 riluzole and 20 placebo participants over 24 months. There was no observed treatment effect with riluzole. Nf light chain (NfL) levels decreased over time (p = 0.007 at 24 months), whereas the Nf heavy chain was unchanged (p = 0.997). Changes in NfL were correlated with EDSS change (p = 0.009) and neuropsychological outcomes. Brain volume decreased more rapidly in patients with high baseline NfL (p = 0.05 at 12 months and p = 0.008 at 24 months) and this relationship became stronger at 24 months (p = 0.024 for interaction). Higher and increasing NfL predicted higher number of gadolinium-enhancing lesions (p < 0.001 for both). CONCLUSIONS: Our findings support the potential value of serum NfL as a marker of neuroaxonal injury in early multiple sclerosis. Its reduction over time could represent regression to the mean, or a possible treatment effect of IFN-β-1a. The association with whole brain atrophy and the formation of acute white matter lesions has relevant implications to use serum NfL as a noninvasive biomarker of the overall consequences of brain damage and ongoing disease activity. CLINICALTRIALSGOV IDENTIFIER: NCT00501943.
OBJECTIVE: To investigate a potential effect of riluzole on serum neurofilaments (Nf) compared to placebo and the relationship between longitudinal clinical and MRI outcomes and serum Nf levels. METHODS: Serum samples were obtained from participants enrolled in a randomized double-blind trial of neuroprotection with riluzole vs placebo as an add-on to weekly interferon-β (IFN-β)-1a IM initiated 3 months after randomization. Nf measurements were performed by ELISA and electrochemiluminescence immunoassay. RESULTS: Longitudinal serum samples were available from 22 riluzole and 20 placebo participants over 24 months. There was no observed treatment effect with riluzole. Nf light chain (NfL) levels decreased over time (p = 0.007 at 24 months), whereas the Nf heavy chain was unchanged (p = 0.997). Changes in NfL were correlated with EDSS change (p = 0.009) and neuropsychological outcomes. Brain volume decreased more rapidly in patients with high baseline NfL (p = 0.05 at 12 months and p = 0.008 at 24 months) and this relationship became stronger at 24 months (p = 0.024 for interaction). Higher and increasing NfL predicted higher number of gadolinium-enhancing lesions (p < 0.001 for both). CONCLUSIONS: Our findings support the potential value of serum NfL as a marker of neuroaxonal injury in early multiple sclerosis. Its reduction over time could represent regression to the mean, or a possible treatment effect of IFN-β-1a. The association with whole brain atrophy and the formation of acute white matter lesions has relevant implications to use serum NfL as a noninvasive biomarker of the overall consequences of brain damage and ongoing disease activity. CLINICALTRIALSGOV IDENTIFIER: NCT00501943.
Authors: Martin Gunnarsson; Clas Malmeström; Markus Axelsson; Peter Sundström; Charlotte Dahle; Magnus Vrethem; Tomas Olsson; Fredrik Piehl; Niklas Norgren; Lars Rosengren; Anders Svenningsson; Jan Lycke Journal: Ann Neurol Date: 2010-12-08 Impact factor: 10.422
Authors: Gerry Shaw; Cui Yang; Rebecca Ellis; Kevin Anderson; J Parker Mickle; Stephen Scheff; Brian Pike; Douglas K Anderson; Dena R Howland Journal: Biochem Biophys Res Commun Date: 2005-11-04 Impact factor: 3.575
Authors: Emmanuelle Waubant; Amir-Hadi Maghzi; Nisha Revirajan; Rebecca Spain; Laura Julian; Ellen M Mowry; Jacqueline Marcus; Shuang Liu; Chengshi Jin; Ari Green; Charles E McCulloch; Daniel Pelletier Journal: Ann Clin Transl Neurol Date: 2014-04-14 Impact factor: 4.511
Authors: Sharmilee Gnanapavan; Donna Grant; Steve Morant; Julian Furby; Tom Hayton; Charlotte E Teunissen; Valerio Leoni; Monica Marta; Robert Brenner; Jacqueline Palace; David H Miller; Raj Kapoor; Gavin Giovannoni Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240
Authors: Arie R Gafson; Nicolas R Barthélemy; Pascale Bomont; Roxana O Carare; Heather D Durham; Jean-Pierre Julien; Jens Kuhle; David Leppert; Ralph A Nixon; Roy O Weller; Henrik Zetterberg; Paul M Matthews Journal: Brain Date: 2020-07-01 Impact factor: 13.501
Authors: Mattia Rosso; Cindy T Gonzalez; Brian C Healy; Shrishti Saxena; Anu Paul; Kjetil Bjornevik; Jens Kuhle; Pascal Benkert; David Leppert; Charles Guttmann; Rohit Bakshi; Howard L Weiner; Tanuja Chitnis Journal: Ann Clin Transl Neurol Date: 2020-05-25 Impact factor: 4.511
Authors: Zara A Ioannides; Peter A Csurhes; Andrew Swayne; Philippe Foubert; Blake T Aftab; Michael P Pender Journal: Mult Scler J Exp Transl Clin Date: 2021-06-03
Authors: Jasmini Alagaratnam; Sophia von Widekind; Davide De Francesco; Jonathan Underwood; Paul Edison; Alan Winston; Henrik Zetterberg; Sarah Fidler Journal: BMJ Neurol Open Date: 2021-06-16
Authors: Lenka Novakova; Markus Axelsson; Clas Malmeström; Henrik Imberg; Olle Elias; Henrik Zetterberg; Olle Nerman; Jan Lycke Journal: PLoS One Date: 2018-04-03 Impact factor: 3.240